Jensen-Munroe relapsed in 2023 and was told unfunded, $220,000-a-year drug daratumumab was her “best option”. Unable to afford that, last year she took the second option of a stem cell transplant.

The phase 2 expansion part of the trial assessed the objective response rate (ORR) of intravenous HexaBody-CD38 versus subcutaneous daratumumab in patients with anti-CD38 antibody-naïve relapsed ...